Delivery Order SPE2DB22D3019-SPE2DB22FK3AZ
Award Date 7/1/22
Potential Completion Date 7/5/22
Potential Value $1.1K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a firm fixed price delivery order valued at fifty thousand nine hundred sixty four dollars and sixty six cents ($50,964.66) to Amerisourcebergen Drug Corporation for the provision of twenty million (20,000,000) units of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. Performance will take place at the prime contractor's facility located in Conshohocken, Pennsylvania through September nineteenth, two thousand twenty three (19SEP2023). No subcontractors or set aside...
- The Defense Logistics Agency Troop Support Medical awarded a $3,449 delivery order to Amerisourcebergen Drug Corp for 4562087730 HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The prime contractor, a division of Amerisourcebergen Corporation, will deliver the pharmaceutical products from its location in Conshohocken, Pennsylvania under a firm fixed price contract concluding on September 8, 2023. No subcontractors or set aside designations were identified. This order was issued against an existing DLA...
- Amerisourcebergen Drug Corp has received a firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical for $1,916.05 to supply 4562690670 HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. Performance will take place at Amerisourcebergen's Conshohocken, Pennsylvania headquarters, with completion by November 3, 2023. No set-aside designation was applied to this order, which was awarded against an indefinite-delivery contract held by Amerisourcebergen with the Department of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,039.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on December 3, 2025, with completion scheduled for December 4, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 years and older. This delivery order was competitively awarded without set-aside designation under a firm fixed price contract structure, with performance at the contractor's corporate office location in...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a ceiling value of $2,950.75 and a completion date of July 18, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $127,248.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 12, 2025, with an ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization in adults. This delivery order is a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,209.05 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed price, competitively awarded contract with no set-aside designation. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and older. The contract was awarded on December 17, 2025, with an ultimate completion date of December 18, 2025, and will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $50,548.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 26, 2025, with an ultimate completion date of September 29, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B infection. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a ceiling value of $2,106.20 and a period of performance through May 1, 2025. The contract is not set aside and was awarded as part of AmerisourceBergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC)...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, the prime contractor, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The order has a potential value of $18,927.36 and a completion date of January 23, 2024. The order was not set aside for any specific business type. AmerisourceBergen Drug Corp is a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and...